Tag
A concise, clinician-friendly summary of the 2026 VA/DoD guideline for treating tobacco and nicotine use, focusing on evidence-based pharmacotherapy, counseling, and new recommendations for electronic and smokeless products.
The CASTL trial evaluated efficient combinations of tobacco cessation interventions for smokers undergoing lung cancer screening, identifying loss-framed messaging with nicotine replacement therapy as the most cost-effective strategy.
This review examines the safety and effectiveness of electronic cigarettes as aids to quit smoking, showing increased abstinence rates compared to traditional therapies and no significant serious adverse events reported.
Updated Cochrane review finds nicotine e-cigarettes increase smoking cessation success compared to NRT and non-nicotine e-cigarettes, with no clear difference in serious adverse events.
This cluster-randomized trial evaluated an automated tobacco cessation intervention for parents in pediatric primary care, finding no significant increase in 1-year quit rates but notable improvements in treatment engagement and smoking red
This analysis reveals that varenicline is the most effective and safe pharmacotherapy for smoking cessation in individuals with current or past major depressive disorder, outperforming bupropion and nicotine patches with no increased neurop
Recent trials show no significant difference in smoking cessation rates between e-cigarettes and combination nicotine replacement therapy among patients discharged from inpatient substance use withdrawal services. Longitudinal analyses reve
